Table 3.
Human SLE urine podocyte mRNA studya
| Patient | Age/Gender | Duration of SLE | SCr (mg/dl) | Up:Cr | Renal Biopsy Findings | Unep:AQP2 MR (ULNR = 2.1) | Upod:AQP2 MR (ULNR = 0.26) |
|---|---|---|---|---|---|---|---|
| 1 | 21/F | 2 yr | 1.0 | 5.9 | DPGN (WHO IV), 7/12 crescentic glomeruli, focal mild interstitial scarring | 3.0 | 1.6 |
| 2 | 34/F | 7 yr | 0.9 | 2.9 | Severe DPGN (WHO IV), 3/13 crescentic glomeruli, no interstitial changes | 10.9 | 4.4 |
| 3 | 19/M | 3 mo | 0.8 | 1.6 | Membranous GN (WHO V), no global glomerulosclerosis, diffuse mild interstitial fibrosis | 3.1 | 1.4 |
| 4 | 41/F | >11 yr | 0.7 | 4.3 | Membranous GN (WHO V), mild focal proliferation, no glomerulosclerosis, focal mild interstitial fibrosis | 0.2 | 0.1 |
a
DPGN, diffuse proliferative glomerulonephritis; SCr, serum creatinine; ULNR, upper limit of normal range; Unep, urine nephrin; Upod, urine podocin; Upr:Cr, urine protein-creatinine ratio; WHO, World Health Organization.